Actualités et Activités de Fractyl Laboratories
Dirigeants
Voir l'organigramme avec ses 23 principaux dirigeants
Biographies les plus recherchées chez Fractyl Laboratories
Changements de dirigeants chez Fractyl Laboratories
- Jonathan Labinger, a rejoint l'entreprise comme Payable Accountant (publié le 20 mai 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Fractyl Laboratories.
Biotechnologie
Fractyl Laboratories a 2 350 concurrents dont Astellas Gene Therapies (Etats—Unis), Eurofins (Luxembourg) et Lonza (Suisse).
Actualités en fusion/acquisition en Biotechnologie.
- Sirius Therapeutics vient d'annoncer une levée de fonds de 50 millions de dollars. (publié le 16 juin 2025).
- BioNTech has announced the acquisition of CureVac (publié le 12 juin 2025).
- SpliceBio vient d'annoncer une levée de fonds de 135 millions de dollars. (publié le 11 juin 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Fractyl Laboratories
- Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 | Fractyl Health, Inc.
- Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort | Fractyl Health, Inc.
- Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | Fractyl Health, Inc.
- Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | Frac
- Fractyl Health to Participate in the Upcoming December Conferences | Fractyl Health, Inc.
- Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates | Fractyl Health, Inc.
- Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024 | Fractyl Health, Inc.
- Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024 | Fractyl Health, Inc.
- News Releases | Fractyl Health, Inc.
- Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024 | Fractyl Health, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Fractyl Laboratories
- Fractyl Laboratories sur Wikipédia, Google News & Yahoo Finance en 1-click
- Fractyl Laboratories sur LinkedIn, Twitter & YouTube en 1-click
